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Background: The Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) showed that treatment
of pregnant women with mild gestational diabetes mellitus is beneficial for both women and their infants. It is still
uncertain whether there are benefits of similar treatment for women with borderline gestational diabetes.
This trial aims to assess whether dietary and lifestyle advice and treatment given to pregnant women who screen
for borderline gestational diabetes reduces neonatal complications and maternal morbidities.
Methods/design: Design: Multicentre, randomised controlled trial.
Inclusion criteria: Women between 240 and 346 weeks gestation with a singleton pregnancy, a positive oral glucose
challenge test (venous plasma glucose ≥7.8 mmol/L) and a normal oral 75 gram glucose tolerance test (fasting
venous plasma glucose <5.5 mmol/L and a 2 hour glucose <7.8 mmol/L) with written, informed consent.
Trial entry and randomisation: Women with an abnormal oral glucose tolerance test (fasting venous plasma glucose
≥5.5 mmol/L or 2 hour glucose ≥7.8 mmol/L) will not be eligible and will be offered treatment for gestational
diabetes, consistent with recommendations based on results of the ACHOIS trial. Eligible women will be
randomised into either the ‘Routine Care Group’ or the ‘Intervention Group’.
Study groups: Women in the ‘Routine Care Group’ will receive routine obstetric care reflecting current clinical
practice in Australian hospitals. Women in the ‘Intervention Group’ will receive obstetric care, which will include
dietary and lifestyle advice, monitoring of blood glucose and further medical treatment for hyperglycaemia as
appropriate.
Primary study outcome: Incidence of large for gestational age infants.
Sample size: A sample size of 682 women will be sufficient to show a 50% reduction in the risk of large for
gestational age infants (alpha 0.05 two-tailed, 80% power, 4% loss to follow up) from 14% to 7% with dietary and
lifestyle advice and treatment.
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Discussion: A conclusive trial outcome will provide reliable evidence of relevance for the care of women with
borderline glucose intolerance in pregnancy and their infants.
Trial registration: Australian New Zealand Clinical Trials Registry - ACTRN12607000174482
Keywords: Borderline gestational diabetes, Gestational diabetes mellitus, Randomised controlled trial, Diet, Lifestyle,
Large for gestational ageBackground
Gestational diabetes mellitus: the burden of disease
The prevalence of gestational diabetes mellitus (GDM) is
rising worldwide [1,2], with recent Australian estimates
indicating that between 5.2% and 8.8% of pregnant
women develop GDM [3]. Risk factors for GDM include
the mother’s own birthweight, maternal obesity,
advanced maternal age, ethnicity, family history of dia-
betes and a previous history of GDM, large babies or un-
explained stillbirth [4-6].
In Australia each year, between 6.3% and 7.7%, or be-
tween 15,900 and 19,450 pregnant women have a posi-
tive oral glucose challenge test (OGCT) on screening for
GDM followed by a normal diagnostic oral glucose toler-
ance test result (OGTT) [7-9]. These women have bor-
derline gestational diabetes with values of glucose
tolerance intermediate between normal and those diag-
nostic of GDM.
There are well-documented risks for the infant of a
mother with GDM including fetal macrosomia, birth
injuries such as shoulder dystocia [10], bone fractures
and nerve palsies [11], neonatal hypoglycaemia [12],
and hyperbilirubinaemia [13]. A later complication
associated with macrosomia and large-for-gestational
age, for female offspring, is premenopausal breast
cancer [14]. Long-term adverse health outcomes
reported for the infants include obesity [6,15],
impaired intellectual achievement [16], impairment of
glucose tolerance [17] and increased risk for subse-
quent diabetes [6].
For women with GDM there is an increased risk of
developing pre-eclampsia and an increased need for in-
duction of labour [18,19]. Impaired glucose tolerance in
pregnancy is highly predictive for the later development
of diabetes, with over 50% of women with GDM devel-
oping type 2 diabetes within 10 years of the index preg-
nancy [20]. Although the perinatal risks of GDM are
well documented, the impact of borderline gestational
diabetes on maternal and infant health outcomes is less
clear.
We reported a 10-year audit (1993-2003) on a large
cohort of women (16,975) at the Women’s and Chil-
dren’s Hospital, Adelaide, that examined the influence of
differing levels of glucose tolerance on pregnancy com-
plications [8]. Women were offered screening for GDMusing an oral glucose challenge test (OGCT). Women
who screened positive (plasma glucose concentration
≥7.8 mmol/L) were offered a 75 gram diagnostic oral
glucose tolerance test (OGTT). Of the women with a
positive OGCT who had an OGTT performed, 1074
(6.3% of all women screened) had normal OGTT results.
Women with borderline gestational diabetes (positive
OGCT, normal OGTT) had a statistically significant
increased risk of pre-eclampsia and caesarean section
compared with women with normal glucose tolerance
(negative OGCT), while the infants of women with bor-
derline gestational diabetes were at increased risk of
hypoglycaemia and hyperbilrubinaemia, compared with
the infants of women with normal glucose tolerance [8].
The results of our audit are consistent with other ob-
servational studies in the literature, identifying an
increased risk of adverse maternal and infant outcomes
with increasing plasma glucose values [21-23]. A retro-
spective US study of 1813 women reported an associ-
ation between increasing levels of hyperglycaemia and
the risk of pre-eclampsia. Optimisation of glucose con-
trol was found to decrease the risk of pre-eclampsia
[23]. The Toronto Tri-Hospital Study screened over
4,000 women, using an OGCT, and if positive, an
OGTT, between 26 and 28 weeks gestation, and found
increasing degrees of carbohydrate intolerance to be
associated with increased risks of pre-eclampsia, caesar-
ean section, macrosomia and need for neonatal photo-
therapy [21,22]. The international observational study,
HAPO, reported an association of increasing hypergly-
caemia with greater risks of adverse perinatal outcomes
in 25,000 women recruited from over 25 different sites
around the world [24].
We reported on the OGCT results and pregnancy out-
comes of 1814 women recruited into the ACTS antioxi-
dant supplementation randomised trial (ACTS Trial) [7].
These women were in their first pregnancy and recruited
within Australia between 2001 and 2005. The proportion
of women with borderline gestational diabetes (positive
OGCT, normal OGTT) was 7.7% of all women screened.
Women with borderline gestational diabetes (positive
OGCT, normal OGTT) had a statistically significant
increased risk of serious adverse health outcomes, preg-
nancy induced hypertension and caesarean section com-
pared with women with normal glucose tolerance
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line gestational diabetes were at increased risk of macro-
somia (birthweight ≥4.5 kg) and need for admission to
the neonatal nursery.
We consider that there is now compelling evidence of
substantially increased risks of adverse health outcomes
for both mother and infant when women have border-
line gestational diabetes. The question of whether dietary
and lifestyle advice and treatment can reduce these risks
now requires urgent consideration.
Treatment of gestational diabetes mellitus improves
maternal and infant health
The ACHOIS (Australian Carbohydrate Intolerance
Study in Pregnant Women) [18] randomised trial pro-
vided evidence that treatment with dietary advice, blood
glucose testing and, if required, insulin given to women
with mild GDM (fasting glucose <7.0 mmol/L and/or
2-hour glucose ≥7.8 mmol/L but <11.1 mmol/L) signifi-
cantly reduced the rate of serious perinatal complica-
tions (death, shoulder dystocia, bone fracture and nerve
palsy) for the infants from 4% to 1%, relative risk (RR),
adjusted for maternal age, race and parity, 0.33; 95%
confidence interval (CI) 0.14 to 0.75; p=0.01). The num-
ber of women needed to treat to prevent one additional
serious outcome in an infant was 34 (95% CI, 20 to 103).
More infants in the treatment group were admitted
to the nursery but there was a significant reduction
in the number of infants with a birthweight over 4
kg (10% vs 21%). Women in the treatment group had
a higher rate of induction of labour (39% vs 29%) al-
though rates of caesarean section were similar be-
tween treatment groups (31% vs 32%). Three months
after pregnancy, treated women had significantly
lower rates of depression and better scores for health
related quality of life [18].
The ACHOIS trial confirmed that mild GDM is a
pathological entity that, untreated, is associated with
relatively rare but nonetheless significant adverse peri-
natal outcomes, which can be avoided or reduced with
treatment consisting of individualised dietary and life-
style advice, with insulin treatment as necessary [18].
Cost consequences were in the range acceptable to
healthcare funders [25]. The ACHOIS trial provided the
first substantial evidence supporting detection and treat-
ment of mild gestational diabetes [26] and has led to
proposals for routine screening to become the standard
for detection of gestational diabetes in Australia and
elsewhere [27-30].
While the ACHOIS trial clarified that treatment of
women with mild GDM is beneficial, uncertainty
remains whether treatment of women with more border-
line gestational diabetes offers similar benefits. Current
clinical practice for the management of pregnantwomen, who screen positive on OGCT but whose subse-
quent OGTT is normal, is to leave such women ‘un-
treated,’ with reassurance that their results have not
reached the required cut-off for the diagnosis of mild or
more severe GDM.Critical appraisal of the literature: a Cochrane review
We conducted a systematic review, using the best
evidence currently available to assess whether treat-
ment of pregnant women with borderline levels of
glucose intolerance (defined as positive OGCT, nor-
mal OGTT) improves maternal and infant outcomes
[31]. Published randomised controlled trials and
cluster-randomised trials comparing alternative man-
agement strategies for women with borderline GDM
were eligible for inclusion. Pregnant women with
hyperglycaemia who did not meet diagnostic criteria
for GDM, based on OGTT test results as defined
variously by individual trialists according to local
health authorities and professional organizations,
were considered eligible. Interventions included diet-
ary advice (standard or individualized), exercise and
lifestyle advice (standard or individualized) and drug
treatment including insulin and oral drugs. Outcomes
included both maternal and fetal/neonatal health out-
comes, as well as outcomes extending into childhood
and adulthood, and health service costs. We used the
search strategy of the Cochrane Controlled Trials
Register (CENTRAL), MEDLINE, EMBASE, hand-
searches of 30 journals and proceedings of major
conferences as well as weekly current awareness
alerts for a further 44 journals (Date of last search
30 September 2011).
Four studies involving 543 women and their babies
were included [32-35]. Two of the four studies were
from the United States [33,35], one was from Canada
[34] and one from Italy [32]. One study [34] was found
to have a low to moderate risk of bias, with the
remaining three studies at moderate to high risk of bias.
The babies of women receiving management for border-
line gestational diabetes were less likely to be macroso-
mic (birthweight >4000g) (three trials, 438 infants, RR
0.38, 95% CI 0.19 to 0.74) or large-for-gestational age
(three trials, 438 infants, RR 0.37, 95% CI 0.20 to 0.66)
when compared with those in the routine care group.
No significant differences in rates of caesarean section
(three trials, 509 women, RR 0.93, 95% CI 0.68 to 1.27)
or operative vaginal birth (one trial, 83 women, RR 1.37,
95% CI 0.20 to 9.27) were found.
This review found that for pregnant women with
hyperglycaemia who did not meet the diagnostic criteria
to be classified as having GDM or type 2 diabetes, inter-
ventions such as dietary counselling, blood glucose
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in the rates of macrosomia and large for gestational age
babies.
Although the results of this systematic review suggest
benefit in treating women with borderline gestational
diabetes, the review concluded that larger trials are
needed of sufficient power and in other populations to
assess the effects of management of such women on ma-
ternal and infant health outcomes [31].
Aims and objectives of this trial
It is now clear from the ACHOIS trial [18] that treat-
ment of pregnant women with mild GDM, formerly
defined as impaired glucose tolerance, is beneficial for
women and their infants. It is still uncertain whether the
benefits of similar treatment for women with borderline
gestational diabetes outweigh any harms from such
treatment.
The aims of this multicentre randomised clinical trial
are to assess whether dietary and lifestyle advice and
treatment given to pregnant women who have border-
line gestational diabetes on screening for GDM (defined
as a positive OGCT followed by a normal OGTT),
reduces neonatal complications and maternal risks.
Hypotheses
The primary hypothesis is that dietary and lifestyle ad-
vice and treatment given to women who have borderline
gestational diabetes on screening for GDM will reduce
the incidence of large for gestational age infants, defined
as birthweight above the 90th centile for gestation and
fetal sex on standardised birthweight charts.
The secondary hypotheses are that dietary and lifestyle
advice and treatment given to women who have border-
line gestational diabetes will reduce the risk of death or
serious health outcome for the infant; reduce the risk of
serious health outcome for the woman; reduce the risk
of other causes of infant morbidity; and reduce the risks
of other adverse health outcomes for the woman.
Methods/design
Ethics statement
Ethics approval was granted by the Children’s Youth and
Women’s Health Services Human Research Ethics Com-
mittee at the Women’s and Children’s Hospital
(REC1860/8/09) and by the local institutional review
boards for each centre.
Study design
Multicentre, randomised, controlled trial.
Inclusion criteria
Women between 240 and 346 weeks gestation with a
singleton pregnancy, with a positive OGCT (venousplasma glucose ≥7.8 mmol/L) and a normal 75 gram
OGTT (fasting venous plasma glucose <5.5 mmol/L and
a 2 hour glucose <7.8 mmol/L), who give written,
informed consent.
Exclusion criteria
Women with known diabetes mellitus, previously treated
GDM, active chronic systemic disease (except essential
hypertension and mild forms of asthma) or a multiple
pregnancy.
Trial entry
Women who are positive for the OGCT screening will
be given the study information sheet, counselled prior to
their OGTT, and entered into the trial if they give con-
sent and have a normal OGTT result. Women with an
abnormal OGTT result (OGTT fasting ≥5.5 mmol/L or
2-hour ≥7.8 mmol/L) are not eligible for the trial and
will be offered treatment for GDM, consistent with
recommendations based on the results of the ACHOIS
trial [18].
Study groups and management
Eligible women with borderline gestational diabetes will
be randomised into one of two study groups: either the
‘Routine Care Group’ or the ‘Intervention Group’.
Randomisation
A telephone randomisation service will use a randomisa-
tion schedule with balanced variable blocks, prepared by
an investigator not involved with recruitment or clinical
care. Stratification will be by OGCT result (venous
plasma glucose <8.0 mmol/L and ≥8.0 mmol/L) and by
collaborating hospital. During the randomisation call,
eligibility will be checked and information collected to
enable stratification and to assist in follow-up. Informa-
tion will be collected on baseline demographic charac-
teristics and previous pregnancy outcomes.
Trial entry questionnaires
At trial entry, women will be asked to complete a ques-
tionnaire relating to quality of life (as measured using
the SF36 Health Survey Questionnaire) [36], satisfaction
with care, anxiety (as measured by the Short Form Spiel-
berger State Trait Inventory) [37], depression (as mea-
sured by the Edinburgh Postnatal Depression Scale) [38],
physical activity [39] and other lifestyle factors that influ-
ence maternal weight gain in pregnancy, including a
food frequency questionnaire [40].
Treatment schedules
Intervention group
Women in the ‘Intervention Group’ will be advised that
their OGTT results are normal but that they have
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ric care by the attending obstetric team, which will in-
clude dietary and lifestyle advice, monitoring of blood
glucose and further treatment if appropriate. The inter-
vention is designed to be able to be incorporated into
routine antenatal care with minimal additional workload
for staff or lengthening of consultation time and to be
acceptable to women. Health professionals at the collab-
orating hospitals have agreed to follow the consensus
recommendations below, based on dietary regulation,
lifestyle modification and blood glucose monitoring.
a) Dietary and lifestyle advice
Women will be given individualised advice regarding their
diet from a qualified dietician, based on published recom-
mendations of the Dietitians Association of Australia,
which are culturally appropriate and which meet the
nutritional requirements of pregnancy. The following
characteristics of the woman: age, pre-pregnancy weight,
activity level, current dietary intake and weight gain for
the current and any previous pregnancies, will be consid-
ered in developing an individual woman’s diet and exer-
cise plan. Moderate exercise is recognised as an adjunct
to dietary advice [41,42]. Written information will be
given to the woman detailing her dietary and exercise
goals during pregnancy and will be included in her ante-
natal study booklet.
b) Blood glucose assessments
After trial entry women will have blood glucose moni-
toring at each antenatal visit consisting of a single, capil-
lary blood glucose (aiming for either fasting or 1 or 2
hours postprandial). Recommended normal blood glu-
cose ranges for women are fasting <5.5 mmol/L, 1 hour
postprandial <8.0 mmol/L and 2 hours postprandial <7.0
mmol/L [42]. Indications for obstetric and/or physician
review regarding further blood glucose monitoring and
treatment are one capillary blood glucose fasting ≥5.5
mmol/L; one capillary blood glucose ≥9.0 mmol/L; or
two or more 1 hour postprandial ≥8.0 mmol/L, and/or 2
hour postprandial ≥7.0 mmol/L.
c) Further antenatal care
Women will be seen for routine antenatal visits
according to standard practice for each hospital. At
each visit, progress with their dietary and exercise
goals will be reviewed with their health professional
and will be recorded in their antenatal study booklet.
Care of women will otherwise follow routine clinical
practice.
Routine care group
Women in the ‘Routine Care Group’ will be advised that
their OGTT results are normal. They will receiveroutine obstetric care by the attending obstetric team.
Care of women in the ‘Routine Care Group’ will reflect
current clinical practice in hospitals in Australia for
women who screen positive on OGCT but have normal
OGTT results.
Both study groups
All women in the trial will be asked to complete a ques-
tionnaire on health related quality of life [38] at 36
weeks gestation. They will also be asked about their
physical activity [39] and dietary habits [40].
Data collection
Pregnancy, birth and neonatal data will be abstracted
from case notes by the research assistant. A standardised
checklist determining presence and severity of any
shoulder dystocia will be attached to the delivery chart
of all women in the study at the time of randomisation,
and will be completed by the primary care giver present
at the birth.
Primary study outcomes
The primary study outcome will be incidence of large
for gestational age infants defined as birthweight above
the 90th centile for gestation and fetal sex on standar-
dised birthweight charts [43].
Secondary study outcomes
For the infant/child, the secondary study outcomes will
be
 death or serious health outcome including one or
more of fetal death after trial entry; death of a
liveborn infant prior to hospital discharge; severe
intrauterine growth restriction (birthweight < 3rd
centile for gestation and fetal sex on standardised
birth weight charts [43]); severe respiratory distress
syndrome (defined as MAP >10 cmH2O and or FiO2
≥0.80%); chronic lung disease (defined as need for
oxygen at 36 weeks postmenstrual age);
intraventricular haemorrhage grade 3 or 4; cystic
periventricular leukomalacia; retinopathy of
prematurity grade 3 or 4; necrotising enterocolitis;
Apgar score <4 at 5 minutes; seizures at <24 hours
age or requiring two or more drugs to control; tube
feeding ≥4 days; care in neonatal intensive care unit
>4 days; use of ventilation for ≥24 hours. These
definitions of serious infant outcomes are based on
the definitions for adverse outcomes used by the
Australian New Zealand Neonatal Network [44] and
from those considered by experts as important
measures of morbidity at or beyond term [45].
 Other causes of infant morbidity as defined by:
individual components of the composite infant
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neonatal hypoglycaemia requiring treatment (defined
as blood glucose <2.5 mmol/L); shoulder dystocia;
nerve palsy; bone fracture; gestational age at birth;
preterm birth (less than 37 weeks gestation); Apgar
score <7 at five minutes; weight, length, head
circumference, small for gestational age (<10th
percentile for gestation and fetal sex on standardised
birthweight charts [43]); macrosomia (≥4 kg); need
for admission to the neonatal nursery and length of
stay; and need for admission to neonatal intensive
care and length of stay; incidence and severity of
respiratory distress syndrome, use of and length of
mechanical ventilation, intraventricular
haemorrhage on early cranial ultrasound,
periventricular leukomalacia on later cranial
ultrasound, need for oxygen therapy at 28 days or
more of life, use of postnatal steroids, use of
antibiotics in first 48 hours of life, proven systemic
infection in first 48 hours of life, use of antibiotics
after first 48 hours of life, proven systemic infection
after first 48 hours of life; use of surfactant; nitric
oxide for respiratory support; need for inotropic
support; air leak syndrome; retinopathy of
prematurity; patent ductus arteriosus requiring
treatment; number of episodes of proven infection;
proven necrotising enterocolitis; thrombocytopenia;
neonatal encephalopathy (Sarnat Stage 1, 2 or 3)
[46].
For the mother, the secondary outcomes will be
 serious health outcomes up to six weeks postpartum
as defined by one or more of maternal death;
pulmonary oedema; eclampsia; stroke; adult
respiratory distress syndrome; cardiac arrest;
respiratory arrest; placental abruption; haemolysis;
coagulopathy; major postpartum haemorrhage; deep
vein thrombosis or pulmonary embolism requiring
anticoagulant therapy.
 other adverse health outcomes as defined by:
individual components of the composite maternal
outcome; pre-eclampsia [47]; caesarean birth;
induction of labour; need for antenatal
hospitalization and length of stay; antepartum
haemorrhage requiring hospital admission; weight
gain during pregnancy; use of antihypertensive
medication; chorioamnionitis requiring antibiotics
during labour; length of postnatal hospital stay; use
of postnatal antibiotics; and postpartum
haemorrhage (≥500mls).
 Maternal diet and exercise outcomes as measured by
dietary and exercise [39] questionnaires at trial entry
and 36 weeks gestation.Sample size
The incidence of having a large for gestational age infant
is the principal endpoint of the trial. In the Italian trial
[32], 14% of infants born to women in the untreated
group were large for gestational age compared with 6%
in the infants of treated women, a 57% change. A trial of
682 women will be able to show a more conservative
50% reduction in risk of large for gestational age infants
from 14% to 7% with dietary and lifestyle advice and
treatment (5% level of significance, two – tailed alpha,
80% power, 4% loss to follow up).
This size of trial will be powered also to detect import-
ant differences in key secondary outcomes. The rate of
serious health outcome for both the infant and the
woman is 12.9% based on data from women with un-
treated borderline GDM in the Australasian Collabora-
tive Trial of Supplements with vitamin C and vitamin E
for the prevention of pre-eclampsia (ACTS) [7]. The
sample size of 682 women will allow a 51% reduction in
the risk of serious maternal and infant health outcome
from 12.9% to 6.3% to be detected with 80% power.
Analyses and reporting of results
An independent data monitoring committee will be
established, with terms of reference. A multidisciplinary
adverse events committee blinded to treatment alloca-
tion will review the cause of death for all maternal and
infant deaths. These data will be made available to the
independent Data Monitoring Committee. Recruitment
will continue until sample size is reached followed by
completion of data collection and analyses.
The analyses will follow several key steps. Baseline
characteristics of all randomised women will be com-
pared descriptively between the study groups. Outcome
comparisons will be made according to the treatment al-
location at randomisation on an ‘intention to treat’ basis.
Both unadjusted and adjusted analyses will be carried
out. Collaborating centre and OGCT result will be con-
trolled for in all adjusted analyses. The primary outcome
of large for gestational age and the secondary outcomes
based on birth weight will be adjusted for maternal age,
parity, body mass index, socioeconomic status and gesta-
tional age at entry.
Secondary exploratory analyses will consider baseline
covariates that show evidence of imbalance between
study groups and are related to the outcome of interest.
The RRs and 95% CIs will be reported using log bino-
mial regression for binary outcomes. The number
needed to treat to benefit or harm for one adverse out-
come will be calculated for the primary outcome. Con-
tinuous outcomes will be analysed using linear
regression. All model assumptions, including normality,
will be assessed. Statistical significance will be assessed
at the 0.05 level using a two-sided comparative test.
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This project is a multicentre, randomised clinical trial
assessing whether dietary and lifestyle advice and treat-
ment given to women with borderline gestational dia-
betes reduces perinatal morbidity, and evaluates the
effects of such treatment on maternal physical and psy-
chological morbidity.
Systematic review of the literature suggests a reduction
in the risk of large for gestational age infants born to
women receiving treatment for borderline gestational
diabetes. There have, however, been only four small
trials reported to date. Larger, high quality trials of suffi-
cient power to detect differences in clinically relevant
maternal and infant health outcomes are a priority.
This trial will provide evidence on which to guide
practice for the care of women and their infants in these
circumstances. This trial is of considerable importance
given more than 16,000 women are affected each year in
Australia alone. There is continuing uncertainty about
diagnosis and treatment of borderline gestational dia-
betes and a lack of randomised controlled trials to date.
Until data from large, well-designed randomised trials
are available to assess this intervention, it is difficult to
develop meaningful, evidence-based, clinical practice
guidelines. A conclusive outcome will provide important,
reliable evidence of great relevance for the care of the
significant number of women with borderline gestational
diabetes in pregnancy and their infants.
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